Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
NEW YORK — Messner Vetere Berger McNamee Schmetterer/Euro RSCG has won advertising duties for Amgen’s Aranesp following a two-month review, the client confirmed. The New York shop competed against Bates, FCB and Cline, Davis & Mann, all New York, for the estimated $25 million account, sources said.
Aranesp, which was approved in September, is intended for the treatment of anemia in patients with chronic kidney disease. MVBMS referred inquiries to the Thousand Oaks, Calif.-based client.
The drug will compete with Johnson & Johnson’s Procrit, a treatment for anemia caused by chemotherapy.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in